Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Virtuoso Binco Inc. is active in the Biotechnology & Pharmaceuticals technology area, where it currently has 1 pending office action. The prosecution of its patent applications is handled by 1 distinct examiner, reflecting a narrow scope of current activity at the patent office. This concentration suggests that the company is currently focused on a specific pharmaceutical or biological innovation rather than a broad portfolio of diverse technologies.
The data shows that the portfolio is being processed within 1 distinct art unit. ALLEN, MARIANNE P is the busiest examiner assigned to the company, with 1 pending office action currently under review. Because the company only has 1 pending office action in total, this examiner is responsible for the entirety of the active prosecution workload. This focus within the Biotechnology & Pharmaceuticals sector highlights the importance of this specific examiner's evaluation.
Practitioners should recognize that having 1 distinct examiner and 1 distinct art unit simplifies the management of the portfolio. The lack of multiple pending actions reduces the complexity of the prosecution strategy, as all current efforts are directed toward the 1 pending office action managed by ALLEN, MARIANNE P. This allows for a specific response strategy tailored to the examiner's feedback in the Biotechnology & Pharmaceuticals field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEN, MARIANNE P | 1 | 60.1% | +18.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18704831 | MULTISPECIFIC ANTIBODIES FOR TREATING CD47-ASSOCIATED DISEASES | ALLEN, MARIANNE P | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18704831 | MULTISPECIFIC ANTIBODIES FOR TREATING CD47-ASSOCIATED DISEASES | ALLEN, MARIANNE P | 1647 | §112 | Non-Final OA | — | Pending | Apr 25, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVirtuoso Binco Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Marianne P Allen has the most, with 1 of Virtuoso Binco Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
